Flowpro Plumbers & Gasfitters Expands Trusted Plumbing Services to Silverdale, Auckland

Flowpro Plumbers & Gasfitters Expands Trusted Plumbing Services to Silverdale, Auckland
Flowpro Plumbers & Gasfitters has announced the expansion of its full range of plumbing services in Silverdale, Auckland. The company has upgraded its emergency plumbing support to offer round-the-clock assistance for both residential and commercial clients facing urgent plumbing problems.

SILVERDALE, AUCKLAND – Flowpro Plumbers & Gasfitters has announced the expansion of its full range of plumbing services in Silverdale, Auckland. The company has upgraded its emergency plumbing support to offer round-the-clock assistance for both residential and commercial clients facing urgent plumbing problems.

The expanded services include 24/7 emergency response, advanced leak detection, professional drain unblocking, and thorough plumbing maintenance. These offerings build on their established services in bathroom renovations, kitchen upgrades, and specialized plumbing installations.

“Our commitment to Silverdale residents has always been to deliver reliable, efficient plumbing solutions when they need them most,” says Benji, spokesperson for Flowpro Plumbers & Gasfitters. “By boosting our emergency response capabilities, we make sure property owners can get expert help anytime, preventing water damage and restoring normal service fast.”

The improved emergency service addresses critical plumbing issues such as burst pipes, major leaks, and overflowing toilets. The company’s rapid response team arrives fully equipped with tools and replacement parts to solve most problems on the first visit, helping to minimize property damage.

Residential plumbing remains a core focus, with services ranging from routine upkeep to complex system installations. Flowpro’s experienced technicians work efficiently across all types of homes, delivering solutions that emphasize durability, quality, and value.

Commercial plumbing support has also been expanded to meet the demands of Silverdale’s growing business sector. The company now offers tailored maintenance plans for offices, retail locations, and industrial buildings to help avoid costly operational disruptions.

As a trusted plumbing contractor in the region, Flowpro has invested in modern diagnostic tools and specialized staff training. These upgrades allow their team to pinpoint issues quickly and carry out effective repairs with minimal disturbance to the client’s property.

Flowpro has also widened its service coverage to reach more neighborhoods in and around Silverdale, ensuring more residents have access to their full suite of plumbing solutions.

Their plumbing maintenance plans are designed to include routine inspections and preventive care, helping clients avoid emergencies. These programs feature scheduled checks of key systems and components to ensure they remain in optimal condition.

Water heater installation and servicing continue to be a standout offering, with systems ranging from conventional tanks to energy-efficient models. Certified technicians manage everything from system selection to compliant installation.

Pipe repair and replacement services address everything from minor leaks to serious system failures. Using long-lasting materials and expert methods, Flowpro ensures dependable results that reduce the likelihood of repeat issues.

Drain cleaning is handled using professional-grade tools that thoroughly remove clogs without harming pipes. Their approach restores proper drainage for both homes and commercial spaces.

For more information, please contact Benji at https://flowpro.co.nz.

About Flowpro Plumbers & Gasfitters

Established in Auckland, Flowpro Plumbers & Gasfitters provides comprehensive plumbing solutions for residential and commercial properties in Silverdale and surrounding communities. Their diverse service offerings include emergency plumbing, bathroom renovations, kitchen renovations, drain unblocking, leak repairs, leak detection, CCTV drain inspection, backflow prevention, and home water filtration system installation. Operating with a professional, customer-focused approach, the company delivers reliable service with certified technicians. Flowpro Plumbers & Gasfitters is located at 2/3 Emirali Road, Silverdale 0932, New Zealand, and can be reached at (09) 802 4984 or via email at plumbing@flowpro.co.nz.

Contact information

Flowpro Plumbers & Gasfitters

2/3 Emirali Road, Silverdale 0932, New Zealand

+64 (09) 802 4984

plumbing@flowpro.co.nz

https://flowpro.co.nz

Media Contact
Company Name: Flowpro Plumbers & Gasfitters
Contact Person: Benji
Email: Send Email
Phone: +6498024984
Address:2/3 Emirali Road
City: Silverdale 0932
Country: New Zealand
Website: https://flowpro.co.nz/

Diabetic Macular Edema Pipeline Outlook Report 2025: Key 45+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Diabetic Macular Edema Pipeline Insight 2025” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Macular Edema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Diabetic Macular Edema Research. Learn more about our innovative pipeline today! @ Diabetic Macular Edema Pipeline Outlook

Key Takeaways from the Diabetic Macular Edema Pipeline Report

  • In August 2025, Bayer announced a study treatment, 8 milligram (mg) aflibercept is injected into the eye. It works by blocking a protein called vascular endothelial growth factor (VEGF) which causes abnormal growth and leakage of blood vessels at the back of the eye. Researchers are looking for a better way to treat people who have diabetic macular edema.
  • In July 2025, Genentech Inc. conducted a study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME). The study consists of 2 segments: Phase I (Parts 1-4) and Phase II (Part 5). Phase I investigated the safety of RO7446603 following a single and multiple intravitreal (IVT) doses as monotherapy or co-administered with IVT aflibercept or IVT faricimab (in separate injections). Phase II will investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of two dose levels of RO7446603 in combination with faricimab, with the two drugs co-mixed and administered as a single IVT injection, compared to faricimab alone. The first participant was enrolled in the Phase I segment on June 22, 2022. Phase I has been completed.
  • In July 2025, Hoffmann-La Roche organized a study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).
  • DelveInsight’s Diabetic Macular Edema Pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Diabetic Macular Edema treatment.
  • The leading Diabetic Macular Edema Companies such as Oculis, 4D Molecular Therapeutics, Ashvattha Therapeutics, Ocugen, AiViva BioPharma, Inc., Unity Biotechnology, Inc., Therini Bio Pty Ltd, Valo Health, Inc., Kyowa Kirin Co., Ltd., Invirsa, Inc., Frontera Therapeutics, EyePoint Pharmaceuticals, Inc., EyeBiotech Ltd., EnnovaBio, Eclipse Life Sciences, Inc., Merck & Co, Rezolute, Inc., Aviceda Therapeutics, KODIAK SCIENCES INC., AsclepiX Therapeutics and others.
  • Promising Diabetic Macular Edema Pipeline Therapies such as Ranibizumab, Avastin (Bevacizumab), Ozurdex (dexamethasone), EXN407, IBE-814 70ug, Dexamethasone nanoparticles eye drops, EYP-1901 and others.

Discover groundbreaking developments in Diabetic Macular Edema therapies! Gain in-depth knowledge of key Diabetic Macular Edema Clinical Trials, emerging drugs, and market opportunities @ Diabetic Macular Edema Clinical Trials Assessment

Diabetic Macular Edema Emerging Drugs Profile

  • OCS-01: Oculis

OCS-01 is an innovative high concentration eye drop candidate to treat DME. It is developed with the proprietary OPTIREACH® technology to enable drug passage from the anterior to the posterior segment of the eye following topical application, a route of administration that contrasts with currently available DME therapies, all requiring invasive delivery to reach the retina, such as ocular implants or intravitreal injections. The OPTIREACH® solubilizing formulation technology addresses the main limitations of conventional eye drops by improving the solubility of lipophilic drugs, increasing the residence time on the eye surface and thereby enabling the drug passage from the eye surface to the posterior segment of the eye. Currently, the drug is in Phase III stage of its development for the treatment of Diabetic Macular Edema.

  • 4D-150: 4D Molecular Therapeutics

4D-150 combines the customized and evolved intravitreal vector, R100, and a transgene cassette that expresses both aflibercept and a VEGF-C inhibitory RNAi. This dual-transgene payload inhibits four members of the VEGF angiogenic family of factors that drive wet AMD and DME: VEGF A, B, C and PlGF. R100 was invented at 4DMT through the proprietary Therapeutic Vector Evolution platform. 4D-150 is designed for single, low-dose intravitreal delivery for transgene expression from the retina without significant inflammation. Currently, the drug is in Phase II stage of its development for the treatment of Diabetic Macular Edema.

  • D-4517.2: Ashvattha Therapeutics

D-4517.2 is a potent anti-angiogenic nanomedicine (“dendranib”) that crosses the blood-retinal barrier and selectively targets activated microglia, macrophages and retinal pigment epithelial cells in the eye. D-4517.2 has the potential to change the current treatment paradigm for neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME) by offering an at-home dosing option by a subcutaneous route of administration rather than delivery via intravitreal injection (injection into the eye). Currently, the drug is in Phase II stage of its development for the treatment of Diabetic Macular Edema.

  • OCU200: Ocugen

OCU200 is a biologic product candidate in development for treating severely sight-threatening diseases like diabetic macular edema (DME), diabetic retinopathy (DR), and wet age-related macular degeneration (Wet-AMD). OCU200 is a novel fusion protein consisting of two human proteins, tumstatin and transferrin, that are already present in retinal tissues. OCU200 has unique features, which enable it to efficiently target leaky blood vessels, regress the existing abnormal blood vessels, and inhibit the growth of new blood vessels in the retina and choroid. Tumstatin, which acts as an anti-VEGF, anti-inflammatory, and anti-oxidative agent, is the active component of OCU200. It binds to integrin receptors, which play a crucial role in disease pathogenesis. Transferrin facilitates the targeted delivery of tumstatin into the retina and choroid and potentially helps increase the interaction between tumstatin and integrin receptors. Currently, the drug is in Phase I stage of its development for the treatment of Diabetic Macular Edema.

  • AIV007: AiViva BioPharma, Inc.

AIV007 is a novel formulation using JEL™ Technology designed for prolonged drug release. AIV007 targets multiple pathways including VEGFR, PDGFR, and FGFR to address neovascularization and fibrosis, and it also modulates TGFβ1 mRNA expression and TGFβ1 levels to reduce collagen production and scarring. In nonclinical in vivo studies for nAMD, AIV007 demonstrated safety, efficacy, and prolonged treatment duration with a single intravitreal administration. Ocular safety and effects in the reduction of neovascularization and fibrosis were observed in several nonclinical animal models and patients. Currently, the drug is in Phase I stage of its development for the treatment of Diabetic Macular Edema.

Diabetic Macular Edema Market Drivers

  • Advances in Diabetic Macular Edema Treatment
  • Improved Diagnostic Tools

Diabetic Macular Edema Market Barriers

  • Diabetic Macular Edema Patient Adherence
  • Side Effects and Safety Concerns associated Diabetic Macular Edema

The Diabetic Macular Edema Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Macular Edema with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Macular Edema Treatment.
  • Diabetic Macular Edema Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Diabetic Macular Edema Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Macular Edema market

Stay informed about the Diabetic Macular Edema pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Diabetic Macular Edema Unmet Needs

Diabetic Macular Edema Companies

Oculis, 4D Molecular Therapeutics, Ashvattha Therapeutics, Ocugen, AiViva BioPharma, Inc., Unity Biotechnology, Inc., Therini Bio Pty Ltd, Valo Health, Inc., Kyowa Kirin Co., Ltd., Invirsa, Inc., Frontera Therapeutics, EyePoint Pharmaceuticals, Inc., EyeBiotech Ltd., EnnovaBio, Eclipse Life Sciences, Inc., Merck & Co, Rezolute, Inc., Aviceda Therapeutics, KODIAK SCIENCES INC., AsclepiX Therapeutics and others.

Diabetic Macular Edema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Diabetic Macular Edema Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Transform your understanding of the Diabetic Macular Edema Pipeline! See the latest progress in drug development and clinical research @ Diabetic Macular Edema Market Drivers and Barriers, and Future Perspectives

Scope of the Diabetic Macular Edema Pipeline Report

  • Coverage- Global
  • Diabetic Macular Edema Companies- Oculis, 4D Molecular Therapeutics, Ashvattha Therapeutics, Ocugen, AiViva BioPharma, Inc., Unity Biotechnology, Inc., Therini Bio Pty Ltd, Valo Health, Inc., Kyowa Kirin Co., Ltd., Invirsa, Inc., Frontera Therapeutics, EyePoint Pharmaceuticals, Inc., EyeBiotech Ltd., EnnovaBio, Eclipse Life Sciences, Inc., Merck & Co, Rezolute, Inc., Aviceda Therapeutics, KODIAK SCIENCES INC., AsclepiX Therapeutics and others.
  • Diabetic Macular Edema Pipeline Therapies- Ranibizumab, Avastin (Bevacizumab), Ozurdex (dexamethasone), EXN407, IBE-814 70ug, Dexamethasone nanoparticles eye drops, EYP-1901 and others.
  • Diabetic Macular Edema Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Diabetic Macular Edema Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

“Stay Ahead in Endocrinology and Metabolic Disorders Research–Access the Full Diabetic Macular Edema Pipeline Analysis Today! @ Diabetic Macular Edema Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Diabetic Macular Edema: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Diabetic Macular Edema– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. OCS-01: Oculis
  9. Mid Stage Products (Phase II)
  10. Early Stage Products (Phase I)
  11. Preclinical and Discovery Stage Products
  12. Drug Name: Company Name
  13. Inactive Products
  14. Diabetic Macular Edema Key Companies
  15. Diabetic Macular Edema Key Products
  16. Diabetic Macular Edema- Unmet Needs
  17. Diabetic Macular Edema- Market Drivers and Barriers
  18. Diabetic Macular Edema- Future Perspectives and Conclusion
  19. Diabetic Macular Edema Analyst Views
  20. Diabetic Macular Edema Key Companies
  21. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/diabetic-macular-edema-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetic Macular Edema Pipeline Outlook Report 2025: Key 45+ Companies and Breakthrough Therapies Shaping the Future Landscape

Vitiligo Pipeline Outlook Report 2025: Key 18+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Vitiligo Pipeline Insight, 2025” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Vitiligo pipeline landscape. It covers the Vitiligo pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Vitiligo pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Vitiligo Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Vitiligo Pipeline Outlook Report

Key Takeaways from the Vitiligo Pipeline Report

  • In August 2025, Incyte Corporation announced a study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
  • In July 2025, Clinuvel Inc. conducted a CUV105 study will assess the efficacy and safety of afamelanotide and NB-UVB light in patients with vitiligo on the body and face versus NB-UVB light alone.
  • DelveInsight’s Vitiligo pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Vitiligo treatment.
  • The leading Vitiligo Companies such as Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc. and others.
  • Promising Vitiligo Pipeline Therapies such as Ritlecitinib, Upadacitinib, SHR0302Base gel, PF-07038124 0.01%, AMG 714, AMG 714, ruxolitinib, Cerdulatinib 0.37% gel, Afamelanotide and others.

Discover how the Vitiligo treatment paradigm is evolving. Access DelveInsight’s in-depth Vitiligo Pipeline Analysis for a closer look at promising breakthroughs @ Vitiligo Clinical Trials and Studies

Vitiligo Emerging Drugs Profile

  • Afamelanotide: Clinuvel, Inc.

Afamelanotide, developed by Clinuvel, Inc., is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) designed to promote skin pigmentation in individuals with vitiligo. It works by activating melanocortin 1 receptors (MC1R) on melanocytes, stimulating melanin production and distribution in depigmented areas of the skin. Afamelanotide is administered via a subcutaneous implant, offering a systemic approach that may enhance repigmentation, particularly when used in combination with controlled UV light therapy. Its mechanism addresses the underlying pigment loss in vitiligo, aiming to restore skin tone more uniformly and effectively. Currently, the drug is in Phase III stage of its development for the treatment of Vitiligo.

  • VYN201: Vyne Therapeutics Inc.

Repibresib is a pan-bromodomain BET inhibitor designed to be locally administered as a “soft” drug to address diseases involving multiple, diverse inflammatory cell signaling pathways, while providing low systemic exposure. BET proteins play a key role in regulating gene transcription via epigenetic interactions (“reading”). Recent research has identified a key role for these proteins in regulating activation of immune cells, including T cells and B cells, and subsequent inflammatory and fibrotic processes. As epigenetic readers, BET proteins regulate the recruitment of transcriptional factors that are key to the production of several pro-inflammatory cytokines. BET inhibitors have the potential to treat a range of immuno-inflammatory and fibrotic diseases by blocking pro-inflammatory cytokine transcription, with additional potential in myeloproliferative neoplastic disorders. In addition to demonstrating clinical proof-of-concept in vitiligo, repibresib has produced consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity in several preclinical models (using several different routes of administration). Currently, the drug is in Phase II stage of its development for the treatment of Vitiligo.

  • FB102: Forte Biosciences, Inc.

FB102 is a proprietary molecule with potentially broad autoimmune and autoimmune-related applications. The Company’s FB102 program aims to address key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. Significant reductions in NK cell pharmacodynamic marker of FB102 mechanism was observed supporting the in vitro as well as the NHP data and mechanism of action of FB102. A phase 1 healthy volunteer SAD/MAD study was successfully completed and demonstrated a good safety profile. Currently, the drug is in Phase I stage of its development for the treatment of Vitiligo.

The Vitiligo Pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Vitiligo with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vitiligo Treatment.
  • Vitiligo Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Vitiligo Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Vitiligo market.

Get a detailed analysis of the latest innovations in the Vitiligo pipeline. Explore DelveInsight’s expert-driven report today! @ Vitiligo Unmet Needs

Vitiligo Companies

Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc. and others.

Vitiligo pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Vitiligo Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Vitiligo Therapies and key Developments @ Vitiligo Market Drivers and Barriers, and Future Perspectives

Scope of the Vitiligo Pipeline Report

  • Coverage- Global
  • Vitiligo Companies- Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc. and others.
  • Vitiligo Pipeline Therapies-Ritlecitinib, Upadacitinib, SHR0302Base gel, PF-07038124 0.01%, AMG 714, AMG 714, ruxolitinib, Cerdulatinib 0.37% gel, Afamelanotide and others.
  • Vitiligo Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Vitiligo Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Vitiligo drug development? Find out in DelveInsight’s exclusive Vitiligo Pipeline Report—access it now! @ Vitiligo Emerging Drugs and Major Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Vitiligo: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Vitiligo– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Afamelanotide: Clinuvel, Inc.
  9. Mid Stage Products (Phase II)
  10. VYN201: Vyne Therapeutics Inc.
  11. Early Stage Products (Phase I)
  12. FB102: Forte Biosciences, Inc.
  13. Preclinical and Discovery Stage Products
  14. Drug Name: Company Name
  15. Inactive Products
  16. Vitiligo Key Companies
  17. Vitiligo Key Products
  18. Vitiligo- Unmet Needs
  19. Vitiligo- Market Drivers and Barriers
  20. Vitiligo- Future Perspectives and Conclusion
  21. Vitiligo Analyst Views
  22. Vitiligo Key Companies
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/vitiligo-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Vitiligo Pipeline Outlook Report 2025: Key 18+ Companies and Breakthrough Therapies Shaping the Future Landscape

How to Reignite Faith in a Doubting Generation

That You May Believe Offers a Fresh, Faith-Building Journey Through the Miracles of Jesus — Now Just $0.99 (August 1–7, 2025)

When John the Apostle penned the Gospel that bears his name, he left behind not just a biography of Jesus, but a roadmap to belief. His message was clear: “These are written that you may believe…” (John 20:31). In his new book, That You May Believe: The Miracles of Jesus in the Book of John, David P. Staggers brings this powerful declaration to life—offering a clear, accessible exploration of the signs of Jesus and their timeless call to faith.

This theologically sound yet readable guide walks readers through the eight miracles recorded in John’s Gospel, with a simple aim: to help you see Jesus for who He truly is—the Son of God—and to believe in His name.

“This book is a tremendous resource for personal or group Bible study.” —Ken Wooten, M.Div., Grace Theological Seminary

Whether you’re new to the Bible, seeking to reignite your faith, or leading others into deeper truth, That You May Believe is both a study tool and a spiritual spark. Staggers explains not just what Jesus did, but why John included these particular signs—miracles that prove His deity, affirm His identity, and call the reader to personal belief.

Inside This Book, You’ll Discover:

  • A biblical definition of miracles
  • Thoughtful examination of each of the 8 signs in John’s Gospel
  • Why these signs matter in the context of John’s message and our modern world
  • Practical life application and devotional insights

“The miracles were not recorded just to show us what Jesus could do—but to show us who Jesus is.” — Ben Scripture, Ph.D., Biochemistry, University of Notre Dame

LIMITED-TIME PROMO

From August 1st to 7th, That You May Believe is available for just $0.99 on Amazon Kindle and other digital platforms. This is your opportunity to equip your heart—or someone else’s—with a Christ-centered foundation of faith. Grab your copy here:

Media Contact
Company Name: Kharis Media LLC
Contact Person: Rufus Philip
Email: Send Email
Phone: (630) 423-6309
City: Aurora, Chicago
State: IL
Country: United States
Website: https://kharispublishing.com/kp/product/that-you-may-believe

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: How to Reignite Faith in a Doubting Generation

Finding Identity, Hope, and Purpose in a Noisy World

A New Must-Read for the Weary and Overlooked: Nameless but Known by Tamar Miller Now Available for Just $0.99 (August 1–7)

In a world that often forgets the broken, silences the wounded, and overlooks the unseen, Nameless but Known: Six Biblical Women Jesus Met with His Mercy by Tamar Miller arrives as a deeply moving reminder: you are seen, known, and deeply loved by Jesus.

This theologically rich and emotionally honest new release from Kharis Publishing brings to life the unforgettable stories of six unnamed women in the Bible whose lives were radically transformed through an encounter with Christ. These women, though nameless in Scripture, are known by the One who never overlooks the forgotten. With precision and compassion, Tamar Miller reveals how their stories still echo hope today—for any woman (or man) who has ever felt unseen, unheard, or unworthy.

“Your story isn’t over—God’s matchless mercy awaits.”

In Nameless but Known, readers will meet:

  • The divorced woman by the well with a thirst that went deeper than water.
  • The adulterous woman at the center of shame and judgment.
  • The maternal woman in the region whose bold plea stirred Christ’s heart.
  • The sinful woman in town, whose tears rewrote her identity.
  • The disabled woman in the synagogue, bound for years yet not beyond grace.
  • The widowed woman outside the city, desperate in grief, met with divine compassion.

Drawing on biblical narratives and practical insight, Tamar invites readers to observe Jesus’ mercy in action and apply it to their own lives. Each chapter includes personal reflection questions that challenge and comfort—making this an ideal resource for individual study, small groups, or women’s ministries.

LIMITED-TIME PROMO

As part of the official release celebration, Nameless but Known is available for just $0.99 on Amazon Kindle and other ebook platforms from August 1 to August 7, 2025. Grab your copy now and invite a friend to join you on a journey of mercy, healing, and hope.

Amazon: https://www.amazon.com/dp/B0FHM7W3DM/

Barnes and Noble: https://www.barnesandnoble.com/w/1147351679

Walmart: https://www.walmart.com/ip/9781637463321/16336518881

Goodreads: https://www.goodreads.com/book/show/239047993

ABOUT THE AUTHOR

Tamar Miller (MBA, University of Texas, Dallas) is a pastor’s wife, Bible teacher, conference speaker, podcast co-host, and women’s ministry leader. She is also the author of Odd Moms Out: God’s redemptive grace in the lives of five biblical mothers (2022). With a warm heart and unwavering biblical conviction, Tamar continues to minister to women longing to encounter the depth of Christ’s compassion.

EARLY PRAISE FOR NAMELESS BUT KNOWN

This is a must-read for those longing to grasp the depths of God’s compassion and grace.” — Whitney Eaton, Director of Ministry to Women, Providence Church

Tamar invites readers to see themselves in these stories… and be reminded that your story is still unfolding in His hands.” — Mark Bricker, Discipleship Pastor

A timely message for every soul yearning to be known. Jesus sees you.” — Sarah Lightner, Missionary and Author

Nameless but Known is more than a book—it’s an invitation into the heart of Christ. For the woman drowning in guilt, the mother fighting discouragement, or the believer desperate for a reminder that God’s mercy still reaches deep—this is your message.

Get your copy today and share the hope: Amazon Kindle – $0.99 promo until August 7

ISBN: 978-1-63746-332-1 | Publisher: Kharis Publishing | 140 pages

Media Contact
Company Name: Kharis Media LLC
Contact Person: Rufus Philip
Email: Send Email
Phone: (630) 423-6309
City: Aurora, Chicago
State: IL
Country: United States
Website: https://kharispublishing.com/kp/product/nameless-but-known/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Finding Identity, Hope, and Purpose in a Noisy World

Challenging Injustice with Faith: A Courageous Conversation on Morality and Equity

Is It Just? Reclaim the Vision of Justice Through the Lens of Jeremiah — 5-Day Ebook Promo: Get It for $0.99 (August 1–7, 2025)

With injustice dominating headlines and division fracturing communities, many believers are asking: Where is God in all of this? In his powerful new book, Is It Just? A Thematic Study of the Book of Jeremiah, Bible teacher Trevor Whitman issues a sobering but hopeful challenge to the Church: return to the heart of God—a God who demands justice, calls for repentance, and invites us into His redemptive presence right now.

Is It Just? is a compelling, accessible, and convicting thematic guide through one of Scripture’s most misunderstood prophetic books. More than a Bible study, it’s a call to inventory our lives and communities, asking: Are we aligned with God’s justice—or merely playing religion while neglecting the most vulnerable among us?

“If your Christianity only looks forward to heaven and ignores the injustice in front of you, it isn’t biblical Christianity.” —Trevor Whitman

What You Will Discover in Is It Just?

  • A fresh, thematic overview of the book of Jeremiah that doesn’t compromise depth or context.
  • Clear guidance on how ancient prophetic warnings speak directly to today’s church and society.
  • An exploration of key themes: justice, idolatry, repentance, self-sufficiency, and God’s enduring faithfulness.
  • Insightful discussion questions at the end of each chapter, perfect for groups or personal study.
  • A sharp challenge: Stop idolizing comfort, start embodying compassion.

Praise from Ministry Leaders & Pastors

“This book helps you hear the heart of God for justice and see yourself as an agent of that justice.” — Bo Noonan, Lead Elder, New Community Church Tacoma

“A powerful and timely call to examine our hearts and trust God’s promises. This is a must-read.” — Aaron Gentile, Family Life Pastor, Life Center Tacoma

“Trevor’s thoughtful approach lets Jeremiah guide readers into deeper formation and renewal.” — Brian Wilson, Dean of Students, Cascade Christian Schools

“Trevor connects Jeremiah’s prophetic warnings to our daily walk with stunning clarity.” — Tim Kuykendal, Director of Athletics, Vertical Sports Maui

“A refreshing, convicting study that makes the voice of the prophet impossible to ignore.” — Rachel Snodgrass, Child & Family Therapist, Puyallup Tribal Health Authority

LIMITED-TIME PROMOTION

To celebrate its release, Is It Just? is available for just $0.99 in eBook format from August 1–5, 2025. Find it on your favorite platform:

Media Contact
Company Name: Kharis Media LLC
Contact Person: Rufus Philip
Email: Send Email
Phone: (630) 423-6309
City: Aurora, Chicago
State: IL
Country: United States
Website: https://kharispublishing.com/kp/product/is-it-just/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Challenging Injustice with Faith: A Courageous Conversation on Morality and Equity

Schneider Electric Launches New Supply Chain Decarbonization Platform

Energy and electrification advisory, services, and software solutions provider Schneider Electric announced today the launch of Zeigo Hub, a new digital platform aimed at helping companies to decarbonize their supply chains, with capabilities to engage with suppliers, build customized decarbonization programs, set targets, and track progress individually by supplier.

Key features of the new platform include guided onboarding of suppliers to enable engagement, a streamlined user interface, and tools to help suppliers calculate and measure emissions, as well as analytics to provide real-time visibility into emissions trends, and progress toward science-based targets, with data structured to support frameworks and standards including CDP, CSRD and TCFD.

Under the new platform, invited suppliers receive access to tailored decarbonization roadmaps and solution providers, with participation costs covered by the sponsor organization, according to Schneider Electric.

The new platform is the first to be deployed in Schneider Electric’s AI-native ecosystem, launched by the company in May 2025 as part of a multi-year initiative aimed at building an AI-powered ecosystem for sustainability and energy management. The new decarbonization platform includes agentic AI features to enhance the onboarding experience by simplifying data entry with web scraping and uploading tools, customize participation invitations, and provide additional program oversight on behalf of corporate program sponsors.

According to Schneider Electric, the new solution comes to address a need by organizations for progress and transparency on supply chain decarbonization, with increasing pressure from customers, regulators, and other stakeholders to report, disclose, and act on emissions.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schneider Electric Launches New Supply Chain Decarbonization Platform

Factory Farming Is Fueling a Global Crisis: Why Plant-Based Change Is Urgent for Animals, the Planet, and Human Health

Cruelty.farm exposes the widespread cruelty and environmental damage caused by factory farming. It highlights the immense suffering of animals, the massive use of resources like water and land, the role of animal agriculture in climate change, and its impact on global health. The piece urges a shift toward plant-based diets as a solution to ecological destruction and animal exploitation, offering resources for education and action.

As humanity faces interconnected crises—climate change, pandemics, food insecurity, and ecological collapse—evidence continues to mount against one of the most destructive industries on Earth: factory farming. Behind supermarket shelves and fast-food counters lies an invisible empire of mass suffering and environmental degradation. Now, the advocacy platform Cruelty.farm is calling on global citizens, policymakers, and institutions to confront the truth about industrial animal agriculture—and to embrace plant-based change as a critical step forward.

Unseen Cruelty: What Factory Farming Means for Animals

Factory farming subjects animals to lives of confinement, mutilation, and deprivation. Over 92 billion land animals are raised and killed for food each year—99% of them in intensive factory farms. They are often denied space to move, never see daylight, and endure extreme stress, pain, and psychological trauma.

Chickens bred for meat suffer from rapid growth that causes skeletal deformities. Dairy cows are artificially inseminated repeatedly and separated from their calves within hours of birth. Pigs are confined to gestation crates so small they can’t turn around.

These conditions are not anomalies—they are industry norms.

Explore the reality: For Animals – Cruelty.farm

Ecological Destruction: Animal Agriculture and the Planet

Factory farming is a primary driver of environmental collapse, yet it remains one of the most overlooked threats. Consider the following:

  • 77% of global agricultural land is used for livestock and feed, but provides just 18% of the world’s calories.

  • 80% of deforestation in the Amazon is caused by cattle ranching.

  • Producing just 1 kg of beef requires around 15,000 liters of water.

  • Animal agriculture generates more greenhouse gas emissions than the entire global transportation sector.

  • 37% of human-induced methane emissions come from livestock—methane being 80 times more potent than CO₂.

From toxic runoff contaminating rivers to habitat destruction driving extinction, factory farming’s environmental impact is staggering.

Learn more: For the Environment – Cruelty.farm

Human Health: The Hidden Cost of Meat and Dairy

The dangers of factory farming extend far beyond animals and ecosystems. The industry also contributes directly to human suffering:

  • 80% of global antibiotics are used on farmed animals, creating antibiotic-resistant “superbugs.”

  • Zoonotic diseases like swine flu and bird flu often originate in factory farms, making pandemics more likely.

  • Diets high in processed and red meat are linked to cancer, diabetes, heart disease, and obesity.

  • Slaughterhouse workers face high rates of injury, PTSD, and exploitation, often in underregulated, dangerous conditions.

The consequences are clear: factory farming is a direct threat to public health.

Find the full picture: For Humans – Cruelty.farm

Why Go Plant-Based? The Powerful Case for Change

Faced with this overwhelming evidence, the solution becomes clear: transitioning to a plant-based diet is one of the most impactful decisions an individual can make.

Plant-based eating:

  • Reduces your carbon footprint by up to 73%.

  • Frees up land—75% of farmland could be rewilded if the world stopped eating animals.

  • Conserves water and biodiversity.

  • Eliminates complicity in animal suffering.

  • Lowers risk of major chronic diseases.

Contrary to common myths, plant-based diets can meet all nutritional needs and offer a path toward a more just, sustainable food system.

Explore the reasons to make the change: Why Go Plant-Based – Cruelty.farm

From Awareness to Action: What You Can Do

Cruelty.farm invites everyone—whether just learning about these issues or already taking steps—to take meaningful action today. The platform offers:

  • Practical guides to shifting toward plant-based diets

  • Vegan meal planning and nutrition support

  • Tips for effective advocacy and myth-busting

  • Campaigns targeting policy reform and corporate accountability

Get involved now: Take Action Now – Cruelty.farm

Final Word

“Factory farming is not just an animal issue. It’s a human issue. It’s a climate issue. It’s a public health issue. We cannot claim to care about justice, sustainability, or the future of our planet while turning a blind eye to one of the most destructive systems we support every day. The time to act is now—and going plant-based is one of the most powerful tools we have.”

Media Contact
Company Name: Humane Foundation
Contact Person: Ali Roghani
Email: Send Email
Address:27 Old Gloucester Street
City: London
State: England
Country: United Kingdom
Website: https://cruelty.farm/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Factory Farming Is Fueling a Global Crisis: Why Plant-Based Change Is Urgent for Animals, the Planet, and Human Health

FaceAestheticsTurkey Sets New Standards in Affordable, High-Quality Facelift Procedures

As the demand for facial rejuvenation grows, more individuals are looking beyond their borders for high-quality, affordable cosmetic surgery. One country that continues to capture global attention is Turkey. From state-of-the-art clinics in Istanbul to world-renowned surgeons with decades of experience, Turkey has established itself as a premier hub for facial aesthetic procedures. But what exactly makes facelift procedures in Turkey so appealing?

In this article, we’ll explore the key reasons why international patients are choosing Turkey for their facial rejuvenation journey, the differences between full and mini facelifts, and how Turkish clinics are redefining cosmetic excellence.

Why Are People Traveling to Turkey for Facelifts?

Turkey’s rise as a global center for cosmetic surgery is no coincidence. Over the last decade, the country has invested heavily in healthcare infrastructure, medical education, and tourism services—transforming the patient experience from start to finish.

1. Advanced Medical Technology & World-Class Facilities

Turkish clinics, especially those in Istanbul, are equipped with cutting-edge technology that rivals leading hospitals in the U.S. and Europe. 3D facial imaging, minimally invasive surgical tools, and advanced anesthesia techniques are standard. These innovations ensure not only precision during surgery but also faster recovery and minimized scarring.

2. Competitive Pricing Without Compromising Quality

One of the most compelling reasons patients opt for a Facelift in Turkey is the cost advantage. A full facelift procedure in Turkey can cost up to 60% less than in many Western countries—without sacrificing safety, quality, or results. Transparent pricing packages often include accommodation, airport transfers, and personalized aftercare, offering peace of mind to international visitors.

Understanding Your Options: Full vs. Mini Facelift

Facelifts are not one-size-fits-all procedures. Depending on your age, skin elasticity, and desired outcome, your surgeon may recommend a full or mini facelift.

Full Facelift

A full facelift targets the lower two-thirds of the face, addressing sagging cheeks, deep nasolabial folds, and jowls. It provides the most comprehensive and long-lasting results, often combined with neck lift procedures for a balanced outcome.

Mini Facelift

For those showing early signs of aging or seeking a subtler lift, the Mini Facelift in Turkey is an ideal option. This minimally invasive procedure focuses on the mid-face and jawline, requires smaller incisions, and typically involves a quicker recovery period. It’s a popular choice among patients in their 40s and 50s looking to refresh their appearance without undergoing a major surgery.

The Human Touch: Expertise That Builds Confidence

Turkish plastic surgeons are not only highly trained but also often certified by international boards. Many have studied or worked in the U.S. or Europe, bringing a global perspective to their practice. Clinics such as Face Aesthetics Turkey stand out by combining medical excellence with personalized care. Multilingual teams, in-depth consultations, and a focus on natural-looking results help patients feel understood and supported throughout their journey.

Is a Facelift in Turkey Right for You?

Choosing to have a cosmetic procedure abroad is a deeply personal decision, one that requires trust, research, and careful planning. Turkey’s combination of medical innovation, affordability, and hospitality makes it an increasingly attractive choice for those seeking facial rejuvenation.

Whether you’re looking for a full transformation or a subtle refresh, Turkey offers an experience that balances clinical precision with aesthetic artistry.

If you’re curious about what’s possible, scheduling a virtual consultation is the first step toward discovering the new you—refreshed, confident, and rejuvenated.

Media Contact
Company Name: FaceAesthetics
Contact Person: Dr. Hasan
Email: Send Email
City: Istanbul
Country: Turkey
Website: https://faceaestheticsturkey.co/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: FaceAestheticsTurkey Sets New Standards in Affordable, High-Quality Facelift Procedures

Steel Rebar Market Size 2025 Emerging Demands, Share, Trends, Futuristic Opportunity, Share and Forecast To 2032

The Steel Rebar Market continues to grow steadily, driven by rising infrastructure development and construction activities worldwide. Key companies like ArcelorMittal, Nippon Steel, and Tata Steel are investing in advanced manufacturing and sustainable practices to meet evolving demand. With growing urbanization and government initiatives, the market outlook remains positive for both established players and emerging firms.

The steel rebar market is estimated to be USD 212.9 billion in 2024 and is projected to reach USD 268.4 billion in 2030, at a CAGR of 4.0% from 2025. This report provides a detailed analysis of the industry, highlighting key growth drivers, steel rebar market demand, challenges, market trends, technological advancements, and regional dynamics. Steel rebar, or reinforcing bar, is a steel rod used to strengthen concrete and masonry structures. It offers tensile strength, which concrete lacks, helping to prevent cracking and structural failure under tension. Rebar is usually made of carbon steel and comes in different grades, sizes, and surface finishes to enhance bonding with concrete. It is used in most building projects, bridges, and infrastructure to boost the durability, stability, and load-carrying capacity of reinforced concrete structures.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=176200687

The steel rebar market is divided by type, which includes deformed and mild. Deformed steel bars feature ribs, lugs, and horns on their surface to enhance the bond between concrete and the rebar, reducing the risk of concrete corrosion. They are widely used across various sectors, such as the construction industry, for building bridges and skyscrapers. Their superior tensile strength and durability have gained recognition worldwide for infrastructure and commercial construction. By contrast, mild steel rebar, which is smooth and has much lower tensile strength, is used for smaller projects like garden walls or reinforcing other types of temporary large structures. Although soft rebar is cheaper, its weak adhesion and tendency to slip have led to decreased use in recent years for new building materials.

The steel rebar market is segmented by process into basic oxygen steelmaking (BOS) and electric arc furnace (EAF). The BOS process is the most commonly used method for steel production, primarily in regions with high steel demand and abundant virgin iron ore supplies. It is widely used by integrated steel plants for large-scale manufacturing. Meanwhile, the EAF route is quickly gaining popularity as a flexible, low-carbon option that recycles scrap steel. EAF is especially favored in sustainable steelmaking and circular economy applications. With strict environmental regulations and a plentiful supply of scrap, EAF is expected to grow faster in the steel rebar market.

The steel rebar market is segmented by coating type into plain carbon steel rebar, galvanized steel rebar, and epoxy-coated steel rebar. Plain carbon steel rebar (ASTM A1044, available in ASTM A615, A706, A775, and A996) is made from unfinished-rolled steel and is the most common type of rebar. However, it lacks corrosion resistance, making it unsuitable for moist conditions. Galvanized steel rebar, which is zinc-coated, offers rust and corrosion resistance suitable for coastal or humid environments. Epoxy-coated steel reinforcement (ASTM A775) provides an effective solution for preventing corrosion of steel rebar and prolonging the lifespan of building structures. Increasing focus on infrastructure longevity and reducing maintenance costs is driving demand for coated rebar, especially zinc and epoxy-coated types.

The steel rebar market is also segmented by bar size, which includes #3, #4, #5, #8, and other sizes. #3 rebar, being smaller, is used in light-duty construction such as reinforcing patios, driveways, and residential slabs. #4 and #5 rebar sizes are commonly used for these applications, balancing strength with ease of concrete placement in foundations, walls, and columns in both residential and commercial buildings. Conversely, larger #8 rebar is generally used for heavy-duty projects like bridges, large industrial facilities, and multi-story buildings requiring substantial load-bearing capacity. The selection of bar size depends on structural design, service conditions, and building code requirements for different types of structures.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=176200687

The steel rebar market is segmented based on end-use sector, which includes infrastructure, housing & industrial. The infrastructure vertical is a major revenue contributor due to the huge amount of government spending on roads, bridges, railways, and airports in developing countries. Steel rebar is a must in order to maintain the structure and integrity of these heavy concrete projects. Another significant source of contribution is the housing sector, which is driven by urbanization, population increase, and the requirement for affordable as well as tall apartments. The industrial segment sells steel rebar that is included in the construction of manufacturing plants, warehouses, coal and battery plants, and other industrial facilities. The rising industrialization and the development of energy and logistics systems have been demanding more in this segment. Rebar specifications and quantity are also affected by the specific construction requirements of each sector.

The steel rebar market is studied in five regions: Asia Pacific, Europe, North America, the Middle East & Africa, and South America. Of these, Asia Pacific is leading the market and is projected to experience the fastest CAGR during the forecast period. This is driven by the rapid pace of urbanization, the development of large-scale infrastructure, and the significant government spending on transportation, energy, and housing in countries such as China, India, Indonesia, and Vietnam. Projects such as India’s Smart Cities Mission and China’s Belt and Road Initiative are driving steel rebar demand in the region. North America is a market that is relatively mature, with demand through rehabilitation of aging infrastructure and modernization, particularly in the US and Canada. The U.S. Infrastructure Investment and Jobs Act has increased demand for rebar for bridges, highways, and public transit systems. The market is also witnessing a growing preference for epoxy-coated and corrosion-resistant rebars in light of stringent construction and safety standards. Europe also indicates firm demand, driven by residential renovation, energy-efficient building construction, and earthquake-resistant buildings in Southern and Eastern Europe. South America, led by Brazil and Argentina, is slowly growing, fueled by public infrastructure projects and an increased demand for housing. But economic disruptions could out turn consistent development. The Middle East & Africa coupler for hollow structures market is proving to be a promising market. Continuation of mega projects, including construction sites for Saudi Arabia’s NEOM city and UAE infrastructure development projects, rollout of Vision Plan 2021, and introduction of tourism and energy sources are expected to aid in the long-term demand for high-strength and durable steel rebar in the region.

Steel Rebar Companies

The demand for steel rebar is mainly met by global players. Some of the leading companies involved in the steel rebar market are Nippon Steel Corporation (Japan), ArcelorMittal (Luxemberg), Gerdau S/A (Brazil), Nucor Corporation (US), Commercial Metals Company (US), TATA Steel (India), Steel Authority of India Limited (India), Mechel PAO (Russia), Steel Dynamics, Inc. (US), NLMK Group (Russia), JSW (India), and Baosteel Group Co., Ltd. (China). These companies, amongst many other regional players, fulfill the requirements globally for steel rebar.

Nippon Steel Corporation (Japan)

Formed in 2012 from the merger of Nippon Steel and Sumitomo Metal Industries, Nippon Steel operates globally across five core segments. Its steel division produces sheets, plates, bars, rods, pipes, and machinery parts. The engineering segment focuses on steel plants and heat management systems, while the chemicals arm offers carbon materials and epoxy resins. Its new materials segment manufactures semiconductors, stainless foils, SiC wafers, carbon fiber, and catalytic converter substrates. The company also provides IT solutions through its system services. Nippon Steel operates across North America, Europe, Asia Pacific, the Middle East & Africa, and South America.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=176200687

ArcelorMittal (Luxembourg)

Founded in 2006 via the merger of Arcelor and Mittal Steel, ArcelorMittal is the world’s leading steel producer with operations in 16 countries and customers in 155. It manufactures a broad portfolio including billets, rebar, wire rods, rails, sheet piles, and tubular products. Serving industries like automotive, construction, and energy, it also offers specialized rebar for reinforced concrete. ArcelorMittal holds a leading market position in North America, South America, and Europe.

Gerdau S.A. (Brazil)

Gerdau is Brazil’s largest steel producer and Latin America’s biggest recycler, converting 11 million tonnes of scrap into steel annually. Operating in 10 countries with over 28,000 employees, Gerdau focuses on long steel products across four segments. In Brazil, it produces rebar, shapes, billets, and iron ore. In North America, it offers rebar, bars, and structural steel; in South Africa, rebar and drawn products; and through its Special Steels unit, it provides stainless and specialty bars. Gerdau emphasizes innovation and sustainability across its operations.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/steel-rebar-market-176200687.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Steel Rebar Market Size 2025 Emerging Demands, Share, Trends, Futuristic Opportunity, Share and Forecast To 2032